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Abstract
Background: Necrotizing enterocolitis (NEC) is a neonatal emergency that affects preterm newborns during the 1st weeks of life. 
Diagnosis is made mainly by clinical criteria since no specific diagnostic tests are available. Objective: The objective was to evaluate 
fecal calprotectin (fCal) as a biomarker of gut inflammation to predict NEC in preterm neonates. Methods: Design: Diagnostic test 
evaluation. Inclusion criteria: 102 preterm neonates <36 weeks gestation and within 7 days of birth admitted in Level III neonatal 
intensive care unit (NICU) were recruited from January 2010 to May 2011. Exclusion criteria: Congenital anomalies and overt infection. 
Paired stool samples at day 3 and 7 were analyzed by lateral quantum blue rapid calprotectin assay. Cut-off values of fCal were 
determined among 30 term healthy infants. A structured questionnaire which included gestational age, symptoms at admission, and 
modified Bell’s staging was used to record NEC episodes on day 3 and 7 of admission. Septic screen and radiological tools were done 
as per NICU protocol. Results: 48% were above 34 weeks gestation; 31.3% were of very low birth weight. As per modified Bell’s 
staging on day 3 and 7, 22 and 11 neonates had 1a or above stage, respectively. 15 had features of NEC; of these, 12 were managed 
appropriately and discharged and 3 died. In the receiver-operated curve with fCal >279 µg/g as cutoff, the area under the curve was 
0.652 (95% confidence interval: 0.516-0.789). Day 3 fCal levels were high in 65.7% neonates. Using NEC as outcome, sensitivity of the 
test was 93.3%; specificity was 39%; positive predictive value was 20.8% and negative predictive value was 97.14%. Conclusion: fCal 
has high sensitivity for diagnosing NEC in preterm neonates. However, further research is needed to establish its clinical usefulness.
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Necrotizing enterocolitis (NEC) presents a particular challenge to neonatologists worldwide with the impending possibility of surgical intervention with 
high mortality and uncertain prognosis [1-3]. Diagnosis is made 
purely on the basis of clinical criteria due to lack of a specific 
clinical presentation and a reliable diagnostic test. Bell et al. [4] 
presented an original system for the uniform clinical staging of 
neonates with NEC. The original criteria of Bell were modified 
by other authors to integrate therapeutic and prognostic aspects 
of the disease-systemic, gastrointestinal, and radiographic 
features [5,6]. Identifying prospective biomarkers would offer 
sufficient opportunities for early intervention.
Calprotectin is a calcium and zinc-binding protein normally 
seen as a component of cytosolic part of neutrophils and is 
a dominating granulocyte biomarker, originally discovered 
in 1980 by Fagerhol et al. [7]. Fecal calprotectin (fCal) is 
extremely stable in feces for more than 7 days with concentration 
approximately 6 folds higher than plasma levels. fCal is 
increasingly being evaluated over the last 10 years for pediatric 
and adult gastroenterological disorders such as screening for 
inflammatory bowel disease (IBD) [8,9] and has become the 
standard marker of inflammation in IBD [10]. The standard 
method to measure calprotectin is using an ELISA method. 
However, it requires a skilled personnel, advanced laboratory 
facilities, and many samples (40-80) before the analysis can 
be done. Therefore, this ELISA method can be used only in 
a high output facility. A novel method based on lateral flow 
technology for the determination of fCal has been developed 
by the Bühlmann laboratory in Basel, Switzerland. This can 
be performed by unskilled personnel like a nurse and does not 
require sophisticated laboratory facilities.
In an acute medical situation like NEC, since every hour 
count and a rapid result are needed for medical decision-
making. For these reasons, we used lateral flow technology for 
the determination of fCal in our study. There are few published 
reports on the utility of fCal as a biomarker of gut inflammation in 
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very low birth weight (VLBW) infants [11]. However, not many 
studies have been done in Indian neonates to find out the cut-offs 
in preterm babies to screen NEC and detecting the diagnostic 
value of this biomarker, and hence this study was planned.
MATERIALS AND METHODS
This study was carried from January 2010 to May 2011 at the 
Level III NICU in Kempegowda Institute of Medical Sciences 
and Research Center, Bengaluru. Prior approval was obtained 
from the Institutional Ethics Committee. Written, informed 
consent was obtained from the parents before recruitment to 
the study. A pilot study was performed on 30 term neonates, 
and stool samples were obtained at day and analyzed for 
calprotectin. The values were tabulated, and the mean value 
was taken as the cut off for the diagnostic test. 102 premature 
neonates born at <36 weeks of gestation and age of life 
<7 days were included in the study. Preterm neonates with 
overwhelming active infection at admission either by culture 
proven sepsis and/or band cells and those with major congenital 
anomalies identified at birth were excluded.
Primary outcome was suspected or probable or definite NEC 
episodes during the study period, defined as clinical evidence of 
gastrointestinal and systemic illness, confirmed radiographically 
or intraoperatively. Secondary outcomes were suspected NEC 
or need for surgery for NEC during the study period; length of 
stay in hospital (days); days receiving intravenous fluids, blood/
blood products, and NEC-related adverse events and/or death; 
by 28 days post-delivery or discharge.
Figure 1 depicts the recruitment process. Neonatal 
symptoms at the time of admission to NICU and the episodes 
of NEC at day 3 and 7 were evaluated as per the modified Bell’s 
criteria. We have chosen day 3 and 7 to utilize the data for 
diagnostic testing as per the gold standard of modified Bell’s 
staging. We have not taken the stool samples serially in view 
of the technical difficulty in collection of samples and also the 
cost and availability of rapid testing kits. Using a prospective 
design, we collected data on birth weight in g and gestational 
age according to Ballard scoring. Antenatal steroid usage 
was noted and the classical markers of inflammation such as 
white blood count, platelets, and C-reactive protein (CRP) 
were estimated and correlated with fCal. Hemogram, arterial 
blood gas analysis, blood urea, and serum electrolytes were 
also obtained. Ultrasound scan of abdomen and stool for occult 
blood test were carried out. NEC episodes were staged as per 
Modified Bell’s criteria (Table 1). Neonates were followed-up 
for a month post discharge.
Paired stool samples were collected for calprotectin assay 
which was measured using a rapid assay by lateral flow quantum 
blue assay kits (Bühlmann, Basel, Switzerland). In this method, 
same monoclonal antibody as used in the ELISA is embedded 
on a nitrocellulose (NC) strip, but instead of being conjugated 
to an enzyme, gold particles are used [12]. After a drop (100 ul) 
is applied into the well, these antibodies bound to calprotectin 
molecules migrate down the NC paper to a secondary monoclonal 
antibody where it is arrested. The higher the fCal concentration, 
the more gold would be conjugated and stronger the red color 
of test band. For reading the test band, an electronic reader 
system that quantifies the fCal level in the stools was used. The 
correlation between the ELISA technique and the Quantum blue 
rapid test is typically between 0.93 and 0.96.
Data were analyzed using SPSS for Windows version 17.0. 
(Chicago, USA: SPSS Inc. Released 2008) fCal cut off levels 
were determined using the pilot data set by receiver operated 
curve (ROC) curve. Univariate analysis was carried out for 
the study variables using χ2 and outcomes, namely composite 
outcome of NEC and/or death during hospitalization or within 
28 days of birth (neonatal period) and modified Bell’s at day 
3 (0 vs. 1 and above). Spearman’s correlation test was used 
to evaluate the relationship between fCal and serum CRP. 
Diagnostic test evaluation was carried out using the cut off for 
calprotectin in those with or without modified Bell’s Staging 
1a and above on day 3 and the composite outcome. ROC 
curves were drawn, and areas under the curve were plotted. 
Significance was set was 0.05.
RESULTS
Totally, 102 premature neonates were included in the study. 
76 neonates were inborn and 26 were outborn. Gestation age by 
Ballard Scoring ranged from 28 to 34 weeks and birth weight 
ranged from 700 to 2300 g. 22 neonates had suspected NEC by 
Modified Bell’s staging done at day 3; at day 7, 11 babies had 
Stage 1a or more. 15 preterm babies were noted to progress to 
NEC within a month of birth. Neonatal symptoms at admission 
were tachypnea in 31% and multiple symptoms such as abdominal 
distension, vomiting, and lethargy were noted in 13%. Antenatal 
Figure 1: Recruitment of newborns-organizational flow 
chart
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factors like pregnancy-induced hypertension were present in 
24 mothers of whom 5 had NEC; chorioamnionitis was present 
in 4 mothers and none of the neonates had NEC. 49 mothers 
had received antenatal steroids and 6 neonates developed NEC 
compared to NEC among 9 babies of 53 mothers who did not 
receive steroids. 3 of the 67 neonates who received no feeds 
orally for 3 days had features of NEC compared to 12 out of 35 
who had been kept nil per orally for 4 or more days had NEC 
(odds ratio 11.13; 95% confidence interval [CI] = 2.880-43.017). 
Expressed breast milk was given to 65 neonates and 20 received 
formula feeds. Table 2 shows modified Bell’s staging at days 3 
and 7. CRP data are presented in Table 3.
fCal as a Biomarker
In the pilot study on term babies, the mean value of fCal was 
279 µg/g of stool. This was used as a cutoff point to evaluate 
the utility of fCal at day 3 and day 7. fCal values on day 3 and 
day 7 are shown in Table 4. 43.1% had high fCal; 15 neonates 
progressed to NEC (primary and secondary outcomes). Higher 
fCal had poor outcome and of the 15 with NEC, 14 had high 
fCal. Of the 15 with NEC, only 2 who had Bell’s Stage 2a and we 
could not analyze the relation of high fCal with stages of NEC.
In the evaluation of diagnostic test, ROC curve with area 
under the curve (AUC) is a combined measure of sensitivity 
and specificity and in this study (Figure 2), the AUC was 
0.652 (95% confidence interval was 0.516-0.789).
With a cutoff value ≥280 µg/g, fCal had a sensitivity of 93.3% 
and specificity of 39%. It has positive predictive value of 20.8%, 
negative predictive value 97.14% and diagnostic accuracy of 
47.05% (Table 5). Correlation of fCal with CRP is depicted in 
Table 1: Modified Bell’s staging criteria for NEC
Stage Systemic signs Abdominal signs Radiographic signs
IA suspected Temperature instability, apnea, 
bradycardia, lethargy
Gastric retention, abdominal 
distention, emesis, heme-positive 
stool
Normal or intestinal 
dilation, mild ileus
IB suspected Same as above Grossly bloody stool Same as above
IIA definite, mildly ill Same as above Same as above, plus absent 
bowel sounds with or without 
abdominal tenderness
Intestinal dilation, 
ileus, pneumatosis 
intestinalis
IIB definite, 
moderately ill
Same as above, plus mild metabolic 
acidosis and thrombocytopenia
Same as above, plus absent bowel 
sounds, definite tenderness, with 
or without abdominal cellulitis or 
right lower quadrant mass
Same as IIA, plus 
ascites
IIIA advanced, severely 
ill, intact bowel
Same as IIB, plus hypotension, 
bradycardia, severe apnea, 
combined respiratory and metabolic 
acidosis, DIC, and neutropenia
Same as above, plus signs of 
peritonitis, marked tenderness, 
and abdominal distention
Same as IIA, plus 
ascites
IIIB advanced, severely 
ill, perforated bowel
Same as IIIA Same as IIIA Same as above, plus 
pneumoperit-oneum
DIC: Disseminated intravascular coagulation; NPO: Nil per os or nothing by mouth, NEC: Necrotizing enterocolitis
Table 2: Modified Bell’s staging at days 3 and 7
Modified Bell’s 
staging
Frequency (%)
Day 3 Day 7
Stage 0 80 (78.4) 92 (91.2)
Stage 1a and more 22 (21.6) 11 (10.8)
Total 102 (100.0) 102 (100.0)
Table 3: CRP levels at day 3
CRP (in mg/L) Frequency Percent
≥6 17 16.6
<6 79 77.4
Not done 6 6.0
Total 102 100
CRP: C-reactive protein
Table 4: Day 3 fCal (in µg/g)
fCal value 
(µg/g)
Frequency (%)
Day 3 Day 7
≥280 67 (65.7) 44 (43.1)
<279 35 (34.3) 58 (56.9)
Total 102 (100.0) 102 (100.0)
fCal: Fecal calprotectin
Table 5: Diagnostic test characteristics of fCal with NEC 
as gold standard
Day 3 fCal 
value (in µg/g)
NEC Total
Present Absent
≥280 14 53 67
<279 1 34 35
Total 15 87 102
fCal: Fecal calprotectin, NEC: Necrotizing enterocolitis
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Figure 3. There was no correlation of CRP and baseline fCal 
(r = 0.047, p = 0.647). Organization chart of progression of NEC 
in preterm neonates against fCal values is shown in Figure 4.
DISCUSSION
In this prospective study, we evaluated the risk factors to NEC 
and diagnostic utility of a new biomarker, fCal. High fCal 
levels were shown to correlate with an increased turnover of 
leukocytes in the intestinal barrier and granulocyte migration 
toward intestinal lumen. fCal levels have been reported to be 
much higher during the first few weeks of life both in healthy 
full-term and preterm infants than in healthy adults and children. 
Determining the cut off level is a challenge in utilizing fCal as a 
diagnostic marker. The high fCal may be related to the unusual 
physiology of neonatal gut.
A specific pattern of functioning in the 1st weeks of life is 
characterized by increased transmucosal leakage, as previously 
shown by Walker [13], a phenomenon that ends by the third 
trimester of life, in a process named “closure” as evidenced 
by intestinal permeability studies. In another prospective 
study, done by Campeotto et al. [14], in 69 full-term healthy 
newborns with three groups of feed types (standard infant 
formula, prebiotic infant formula, and breast fed group), 
fCal concentrations (median 167 μg/g) were higher than 
the reference values in the healthy adults. Rouge et al. [15] 
determined cut-off levels using an ELISA assay in 147 samples 
obtained prospectively from 47 preterm babies. Median fCal 
excretion was 138 μg/g. Dynamic change of fCal in VLBW 
infants (gestational age 23-30 weeks, birth weight <1500 g) 
was studied [16]. The fCal levels were not related to gestational 
age or feedings regimen and tend to decrease with increasing 
age (p = 0.121) and feeding volumes (p = 0.179) [16].
Carroll et al. [17] reported utility of fCal in 7 neonates with 
definite NEC and 7 age and gestational age-matched and sex-
matched controls; mean fCal was 288·4 mg/L in patients with 
NEC compared with 98·0 mg/L in controls. In our study, there 
was a statistically significant association with high fCal and 
NEC as 14 of the 67 with elevated fCal and 1 of 35 with normal 
fCal progressed to develop NEC. ROC curve showed that the 
AUC was 0.652 with a 95% CI 0.516 to 0.789. With a cutoff 
value ≥280 µg/g, fCal had a sensitivity of 93.3% and specificity 
of 39%; PPV 20.8% and NPV 97.14% and diagnostic accuracy 
was 47.05%.
Excretion of fCal may vary between persons and 
between points of time of sampling as described in various 
studies [15,18-20]. Hence, correlating an fCal measurement to 
clinical findings of Bell’s score and to the individual’s previous 
fCal measurements may be the most appropriate way to utilize 
fCal in NEC. In a prospective case control study [21], median 
Figure 2: The receiver operating characteristic receiver 
operated curve for fecal calprotectin at day 3 and outcome
Figure 3: Correlation between C-reactive protein and 
baseline fecal calprotectin
Figure 4: Organization chart of progression of necrotizing 
enterocolitis in preterm neonates against fecal calprotectin 
values. ^ ^Remaining 34 neonates had no features suggestive 
of necrotizing enterocolitis as per modified Bell’s criteria. 
**Remaining 46 neonates did not have clinical features of 
necrotizing enterocolitis as per modified Bell’s criteria
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fCal concentrations were 1282 and 365 μg/g at diagnosis in 
infants with NEC and controls, respectively. fCal levels in NEC 
cases were significantly higher than those of the control group 
both in the first sample obtained at diagnosis and subsequent 
sample 3-5 days later. fCal value of 792 μg/g had a sensitivity of 
76% and specificity of 92% for the diagnosis of definite NEC. 
There was correlation between calprotectin concentrations and 
severity of NEC [22].
Comparison of study groups with regard to fCal may be affected 
by many variations. In a previous study [23] on 126 preterm infants 
born at a median gestational age of 33 weeks to evaluate fCal as a 
marker of intestinal distress, ROC curve showed that with cutoff 
values of 363 μg/g, sensitivity was 0.65 and specificity 0.82; at 
cut off 636 μg/g, sensitivity was 0.72, specificity was 0.95 for the 
development of mild or severe enteropathy. Campeotto et al. [24] 
reported high levels of calprotectin (median 196 μg/g) in the 
stool samples, but did not correlate with the infants’ gestational 
age, birth weight, gender, mode of feeding (breast or bottle), or 
postnatal age. Infants in the acute phase of a gastrointestinal event 
experienced a transitory increase in fCal levels, suggesting that 
it may serve as a noninvasively obtained biological marker of 
neonatal intestinal disturbance similar to the one observed in our 
study at day 3 of birth.
Development of NEC in VLBW babies and diagnostic value 
of fCal has been reported recently by Zoppelli et al. [25]. In this 
study, 1899 stool samples were obtained from 206 VLBW infants 
with a mean gestation of age 28.5 weeks. 19 of these infants 
developed NEC; of these 5 had fulminant NEC. fCal levels showed 
significant gestational and postnatal age dependent dynamics 
with particularly low levels in extremely premature infants. 
Sensitivity for discriminating moderate NEC from healthy infants 
and infants with intestinal distress was 0.89 for a cut-off of 180 
and 210 μg/g, respectively, at the onset of symptoms. Specificity 
was 0.96 and 0.84. Fulminant NEC had low fCal and with a cut-
off of <24 μg/g having a sensitivity of 0.84 and a specificity of 
0.72. fCal can be a useful marker in identifying premature infants 
with gastrointestinal distress and NEC in particular. In our study, 
only 2 out of the 15 neonates with NEC had Bell’s Stage 2a and 
because of this small number, we could not analyze the relation 
of high fCal with stage of NEC. Further multicenter studies are 
needed with large sample size to ascertain the diagnostic value 
before fCal can be recommended on a routine basis.
CONCLUSION
fCal has a diagnostic sensitivity of 93.3% and a negative 
predictive value of 97.14%. It is a useful addition to the existing 
methods to screen NEC in preterm infants.
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